DMII on Nasdaq

Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. is a blank check company, listed on Nasdaq (DMII).1 It is headquartered in New York, New York.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerDMII on Nasdaq1
  • IndustryBlank Checks1
  • HeadquartersNew York, New York1
  • Business address420 Lexington Avenue, Suite 1402, New York, Ny 101702
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Chief Financial Officer (the “CFO”) learned that Sponsor would not be able to repay the balance due back to the Company.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Every line of the income statement as filed: the last 1 fiscal year (annual) or 1 quarters (quarterly), latest first.4

Period ending2025-12-31
General and administrative costs$488.4K
Total operating expenses$488.4K
Loss from operations-$488.4K
Interest earned on cash and investments held in Trust Account$4.9M
Gain on extinguishment of over-allotment option liability$553.7K
Provision for credit losses-$812.1K
Total other income$4.7M
Net income (loss)$4.2M

Compare Drugs Made In America Acquisition II Corp. with another company

Corporate structure

Drugs Made In America Acquisition II Corp. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Drugs Made In America Acquisition II Corp.

  • Drugs Made In America Acquisition II LLC Filed SCHEDULE 13D on Drugs Made In America Acquisition II Corp., latest Oct 2, 2025
  • Drugs Made In America Acquisition II Corp. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Drugs Made In America Acquisition II Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2234 Dec 31, 2025

Properties, in its own words

We do not own any real estate or other physical properties materially important to our operations. Our principal executive offices were previously located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301. The cost for this space is included in the $10,000 per month fee that we paid to our sponsor or an affiliate for office space, administrative and support services. We have ceased making the $10,000 per month fee as the agreement has been cancelled in March 2026. Our current executive office is located at 420 Lexington Avenue, Suite 1402, New York, NY. We consider our current office space adequate for our current operations.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led Drugs Made In America Acquisition II Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lynn Stockwell2025–now

Chair

  1. Lynn Stockwell2025–now

Chief financial officer

  1. Glenn C. Worman2025–now
Board members and other officers (3)

Timeline

  1. Apr 28, 20268-K Entered a material agreement12
  2. Apr 3, 20268-K Entered a material agreement; New debt or obligation13
  3. Mar 17, 20268-K Entered a material agreement; New debt or obligation; Other events14
  4. Mar 6, 20268-K Executive or director change15
  5. Mar 6, 20268-K Other events16
  6. Nov 18, 20258-K Executive or director change17
  7. Oct 2, 20258-K Other events18
  8. Sep 29, 20258-K Entered a material agreement; Unregistered sale of shares; Executive or director change19
  9. Sep 24, 2025New chief executive Lynn Stockwell becomes CEO7

Filings

45 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 8 major events, 12 insider forms, 1 large holders, 20 other. The latest 20:

  1. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  2. May 14, 202610-Q QUARTERLY REPORT EDGAR
  3. Apr 28, 20268-K CURRENT REPORT EDGAR
  4. Apr 15, 202610-K ANNUAL REPORT EDGAR
  5. Apr 3, 20268-K CURRENT REPORT EDGAR
  6. Apr 1, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
  7. Mar 17, 20268-K CURRENT REPORT EDGAR
  8. Mar 6, 20268-K EDGAR
  9. Mar 6, 20268-K CURRENT REPORT EDGAR
  10. Nov 18, 202510-Q QUARTERLY REPORT EDGAR
  11. Nov 18, 20258-K CURRENT REPORT EDGAR
  12. Nov 17, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  13. Oct 17, 20254 EDGAR
  14. Oct 2, 20258-K CURRENT REPORT EDGAR
  15. Oct 2, 20254 EDGAR
  16. Oct 2, 2025SCHEDULE 13D EDGAR
  17. Oct 1, 20254 EDGAR
  18. Oct 1, 20254 EDGAR
  19. Oct 1, 20254 EDGAR
  20. Oct 1, 20254 EDGAR

The 45 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 2 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 26, 2025Stockwell LynnCEO and Exe. Chair of BoardBuy700,000Form 4
Sep 26, 2025Stockwell LynnCEO and Exe. Chair of BoardSale7,966,667Form 4
Sep 26, 2025Drugs Made In America Acquisition II LLC10% ownerBuy700,000Form 4
Sep 26, 2025Drugs Made In America Acquisition II LLC10% ownerSale7,966,667Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Drugs Made In America Acquisition II Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDrugs Made In America Acquisition II Corp.1
  • CIK0002040475
  • Employer ID (EIN)98-18156243
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inCayman Islands3
  • Fiscal year endsDecember 311
  • Industry code (SIC)6770 Blank Checks1
  • SEC reviewing officeOffice of Real Estate & Construction, Division of Corporation Finance1
  • Business address420 Lexington Avenue, Suite 1402, New York, NY 101701
  • Phone954-870-31041
  • Shares outstanding63,700,000 as of Aug 14, 20266
  • Public float$0 as of Jun 30, 20254
  • AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 19, 20251
  • Filings45 in all: 8-K (8), 3 (6), 4 (6), CORRESP (4), 10-Q (3), S-1/A (3), UPLOAD (3), 10-K (1)1
    All 19 form types

    424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), NT 10-K (1), NT 10-Q (1), S-1 (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Apr 28, 2026

Securities registered for trading

ClassSymbolExchange
Units, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-tenth (1/10) of an Ordinary ShareDMIIUThe Nasdaq Stock Market LLC
Ordinary SharesDMIIThe Nasdaq Stock Market LLC
RightsDMIIRThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

Legal proceedings

We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. There is currently no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such, and we and the members of our management team have not been subject to any such proceeding.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
  18. 18
    SEC EDGAROther events
  19. 19
  20. 20